Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766947 | 1.00 | APLNR (0.51) | APLNRGBA1 | |
| SCHEMBL20166817 | 1.00 | APLNR (0.51) | APLNRGBA1 | |
| SCHEMBL31324432 | 0.84 | APLNR (0.35) | APLNR | |
| SCHEMBL18245727 | 0.84 | APLNR (0.43) | APLNR | |
| SCHEMBL18246161 | 0.84 | APLNR (0.43) | APLNR | |
| SCHEMBL18247096 | 0.84 | APLNR (0.43) | APLNR | |
| SCHEMBL18245771 | 0.82 | APLNR (0.49) | APLNRGBA1 | |
| SCHEMBL20190471 | 0.81 | APLNR (0.40) | APLNRGBA1 | |
| SCHEMBL19574019 | 0.81 | LMNA (0.43) | APLNR | |
| SCHEMBL18245749 | 0.80 | APLNR (0.46) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4593815-A1 | APELIN RECEPTOR AGONISTS FOR TREATING MUSCLE CONDITIONS | Bioage Labs, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4532015-A1 | APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY | Bioage Labs, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024072907-A1 | APELIN RECEPTOR AGONISTS FOR TREATING MUSCLE CONDITIONS | BioAge Labs, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023235360-A1 | APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY | BioAge Labs, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | AMGEN INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| CN-108137545-B | Triazole agonists of the APJ receptor | 美国安进公司 | 2020-09-22 | — | — | CN | disclosed |
| EP-3541804-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-9573936-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AP3M1, GPBAR1 | APLNR 5/4885GBA1 4717/4885 |
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885GBA1 4460/4885 |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885GBA1 4460/4885 |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885GBA1 4460/4885 |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885GBA1 4460/4885 |
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | APLNR, AGTR1, AGTR2 | APLNR 1/4885GBA1 4661/4885 |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | TBXA2R, AP3M1, GPBAR1 | APLNR 5/4885GBA1 4717/4885 |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885GBA1 4460/4885 |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885GBA1 4460/4885 |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885GBA1 4460/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | APLNR 1/4885GBA1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.